Moreover, the loss of DAB2IP results in elevated PARP-1 protein levels, which are associated with IR resistance in RCC, providing a new targeting strategy to improve the efficacy of radiotherapy of RCC. The gene discussed is PARP1; the disease is renal cell carcinoma.